

Dr. Jorge Gallardo Ballart

Professional profile and biography

Dr. Jorge Gallardo holds a degree in Industrial Engineering from the Escuela Técnica Superior de Ingeniería Industrial in Barcelona and has been the Chairman of Almirall since 1988, having previously held various management positions in the company since 1965 (including that of Chief Executive Officer until 2011). He is a Board member of EFPIA (European Federation of Pharmaceutical Industries and Associations), where he served as President from 1998 to 2000, and Vice President from 1966 to 1998 and from 2000 to 2002; Vice President of Farmaindustria (Spanish association of pharmaceutical industries), where he served as President from 1993 to 1995 and from 2002 to 2004; Board member of IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) since 2004; Numerary Academic of the Royal Academy of Pharmacy of Catalonia, and Academic Correspondent of the National Royal Academy of Pharmacy.

Other significant Boards to which he belongs

Grupo Plafin, S.A., Grupo Corporativo Landon, S.L.

Member category

External proprietary member, linked to Grupo Plafin, S.A. and Grupo Corporativo Landon, S.L.

Date of first appointment, and subsequent appointments

First appointment on 30/06/1997; re-elected on 18/10/2006, 04/05/2012, 09/05/2018 , 08/05/2019 and 07/05/2021.

Company shares, and share options

He is indirect holder, with his brother Antonio through the company Grupo Plafin, S.A., of 72,973,972 company shares, and indirect holder, with his brother Antonio through the company Grupo Corporativo Landon, S.L., of 33,539,172 company shares.

Mr. Gianfranco Nazzi

Professional profile and biography

Gianfranco Nazzi holds a Degree in Economics and Banking Sciences from the University of Udine and a Master's Degree of Business Administration from the Bocconi University of Milan. Mr. Nazzi joins Almirall from Teva Pharmaceuticals Industries Ltd, where he has most recently been serving as Executive Vice President of the International Markets Region and as a member of the Teva Executive Committee. While at Teva over the past seven years, he held roles of increasing responsibility and geographic scope based in Israel and the Netherlands. Mr. Nazzi held the position of Senior Vice President Specialty Medicines Europe and President and CEO Growth Markets Region. Prior to Teva, Mr. Nazzi held a variety of senior positions at Astra Zeneca, GSK and Eli Lilly in commercial and general management roles based in the UK, Italy, Serbia and the US.

Other significant Boards to which he belongs, listed companies or otherwise

None.

Member category to which he belongs, as applicable, and indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

Executive director.

Date of first appointment as company board member, and subsequent appointments

18/02/21, by co-option; reelected by the General Assembly on 07/05/21.

Company shares, and share options, of which he is holder

None.

Sir Tom McKillop

Professional profile and biography

Sir Tom McKillop began his career at ICI where he held various positions before being appointed Technical Director. In 1992 he was appointed deputy CEO and in 1994 he became CEO of Zeneca Pharmaceuticals, leading the merger of Astra and Zeneca in 1999, and becoming CEO of AstraZeneca plc until retiring at the end of 2005. Until 2009, he was the Chairman of the Royal Bank of Scotland and a Non-Executive Director of BP. He has been Chairman or non-executive director of various other healthcare companies and received numerous academic awards and honorary degrees.

Other significant Boards to which he belongs, listed companies or otherwise

Evolva Holding SA. He is also part of the Advisory Board of Alsbridge LLP.

Member category to which he belongs, as applicable, and indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

External member.

Date of first appointment as company board member, and subsequent appointments

First appointment on 29/05/2007. Re-elected on 04/05/2012, 09/05/2018 and 08/05/2019.

Company shares, and share options, of which he is holder

No shares or share options.

Mr. Gerhard Mayr

Professional profile and biography

Mr. Mayr holds a degree in Chemical Engineering from the Swiss Federal Institute of Technology and an MBA from the Stanford Graduate School of Business. He joined Eli Lilly & Company in 1972, where he held management positions in US, Europe, the Middle East, Asia, and Latin America before being appointed President of Lilly International and President of Lilly Intercontinental. He became Executive Vice President of Global Operations in 1998 until retiring in 2004. He served as Non-Executive Director on the boards of Bank Austria, OMV, Lonza, and Alcon. He joined the board of UCB in 2005 and until 2017 was Non-Executive Chairman of UCB. He is a Non-Executive Director of Aragen Lifesciences since 2008, and of Almirall since 2012. He was appointed to the board of the US -Egypt Presidents Council, has served on the board of Project Hope, and on various industry Advisory Boards. He continues to serve on the board of a Family Foundation, on the board of the Vienna Science Research and Technology Fund, and he is Chairman of the Scientific Advisory Board of the University of Vienna. He received Decorations of Honour for services to the Republic of Austria, for services to the State of Vienna, and is the recipient of honours from the State of Indiana and the City of Indianapolis.

Other significant Boards to which he belongs

Aragen Life Sciences (previous GVKBio)

Member category

Independent director.

Date of first appointment, and subsequent appointments.

First appointment on 19/10/2012; re-elected on 08/05/2019 and on 07/05/2021.

Company shares, and share options

None.

Ms. Karin Louise Dorrepaal

Professional profile and biography

Mrs. Dorrepaal has a PhD from the Free University of Amsterdam, and holds an MBA from the Rotterdam School of Management. In 1990 she joined Booz Allen Hamilton, Management Consultants, where she remained until 2004, being appointed Vice President (partner) in 2000. She specializes in the pharmaceutical industry and has advised large companies on strategy, sales, marketing and supply chain issues. In 2004 she was appointed to the Board of Executive Directors of Schering AG. Following the acquisition of this company by Bayer AG, Ms. Dorrepaal left her position. Currently she is on the Board of Directors of Gerresheimer AG, Paion AG, the Kerry Group plc. and several non-listed companies.

Other significant Boards to which she belongs, listed companies or otherwise

Gerresheimer AG, Paion AG, The Kerry Group plc.

Member category to which she belongs as applicable, indicating, for directors representing controlling shareholders, the shareholder she represents or with whom she is linked

Independent.

Date of first appointment as company board member, and subsequent appointments

First appointment on 16/11/2012 by co-option, effective as of 01/01/2013. Re-elected on 08/05/2019.

Company shares, and share options, of which she is holder

None.

Dr. Seth J. Orlow, M.D., Ph.D.

Professional profile and biography

Dr. Orlow holds a Doctor of Medicine and a PhD in Molecular Pharmacology from the Albert Einstein College of Medicine of Yeshiva University (US) and a Bachelor of Science in Biomedical Sciences from Harvard College (US). He serves as a Senior Advisor to Pharus Securities. In the past, Dr. Orlow was, among other roles, partner at Easton Capital Partners, Co-Founder of Anaderm Research Corporation, and Director of Protez Pharmaceuticals and Transave, Inc. Throughout his career, Dr. Orlow has been a Professor in the Departments of Dermatology, Cell Biology, and Pediatrics at the NYU Grossman School of Medicine, where he has also served as Chair of the Ronald O. Perelman Department of Dermatology since 2006.

Other significant Boards to which he belongs

R2 Technologies, Inc.

Member category

Independent director.

Date of first appointment, and subsequent appointments

First appointment on 06/05/2016; re-elected on 23/07/2020 and on 07/05/2021.

Company shares, and share options

None.

Ms. Georgia Garinois-Melenikiotou

Professional profile and biography

Mrs. Garinois-Melenikiotou holds a Degree in Mechanical Engineering from the National Technical University of Athens, and Master's in Management from the Massachusetts Institute of Technology. She is the Executive Vice President of Corporate Marketing at the Estée Lauder Companies, Inc., and Board Member of the MIT Sloan School of Management and Operating Partner at Talomon Capital LTD. Before joining Estée Lauder in 2010, Ms Garinois-Melenikiotou held various management positions up to Global President at Johnson & Johnson, where she remained for 27 years and worked in seven countries.

Other significant Boards to which she belongs, listed companies or otherwise

None.

Member category to which she belongs as applicable, indicating, for directors representing controlling shareholders, the shareholder she represents or with whom she is linked

Independent.

Date of first appointment as company board member, and subsequent appointments
First appointment

First appointment on 06/05/2016 by cooption, effective as of 01/07/2016. Ratified and re- elected on 03/05/2017.

Shares or options on shares in the Company

None.

Mr. Enrique D Leyva Pérez

Professional profile and biography

Mr. De Leyva holds an M.Sc. Degree in Civil Engineering from the Engineering School of Madrid and an MBA from Columbia Business School, where he was a Fullbright Scholar specialised in Finance and Accounting. He has developed his career in top-level companies such as Unión Fenosa (1983-1986) and McKinsey & Company (1986-2006), in various executive positions and countries (including the UK and US), and is currently one of the founding partners of Magnum Industrial Partners, a leading Iberian private equity firm which has launched three funds to the market with c. €1.5 bn of committed capital. He also belongs to the Boards of Directors of Indra as well as several portfolio companies of the Magnum Funds. He has been Chairman or Director of companies in the Education, Energy, Industry, Health Care, B2B Services, and Telecommunications industries.

Other significant Boards to which he belongs

Indra.

Member category

Independent director.

Date of first appointment, and subsequent appointments

First appointment on 22/02/2019 by co-option; re-elected on 08/05/2019 and on 07/05/2021.

Company shares, and share options

17,980 shares

Mr. Carlos Gallardo Piqué

Professional profile and biography

Mr. Gallardo holds an MS in Industrial Engineering from the Universitat Politècnica de Catalunya and an MBA from Stanford University's Graduate School of Business. Prior to joining Almirall, he started his pharmaceutical career at Pfizer, where he held positions of increasing seniority over nearly ten years. Since leaving Almirall as General Manager of the UK and Ireland in 2013, Carlos has been serving as Board Member since 2014 and was appointed Second Vice President of Almirall's Board of Directors in 2020. In parallel, he has established a successful career as an early stage investor in disrupting healthcare technology. He is the founder and CEO of CG Health Ventures, which invests in early stage digital health and medtech companies globally, providing a unique blend of operational support and capital. Mr. Gallardo serves on a number of boards of promising early stage companies.

Other significant Boards to which he belongs

Babyscripts, S-Biomedic

Member category

External proprietary director, linked to Grupo Plafin, S.A. and Grupo Corporativo Landon, S.L.

Date of first appointment, and subsequent appointments

First appointment 25/07/2014 by co-option; re-elected on 07/11/2014, on 08/05/2019 and on 07/05/2021.

Company shares, and share options

Direct holder of 1.000 shares and indirect holder, together with other family members through the company Grupo Plafin, S.A., of 72,973,972 company shares, and indirect holder, together with other family members through Grupo Corporativo Landon, S.L., of 33,539,172 company shares.

Mr. Antonio Gallardo Torrededía

Professional profile and biography

Mr. Antonio Gallardo holds a degree in Business Science from the University of Barcelona and an Executive MBA from the University of Chicago. He also has a Master's degree in Marketing from ESADE. He started his professional career at Akzo Nobel, where he stayed for seven years reaching the position of Marketing Director, and in 1999 he joined Almirall as Area Manager. Later, he was Director of Pharmacy Marketing and developed a loyalty programme consisting of 10,000 pharmacies through the network of medical representatives in Spain, after which he joined the medical visit network as Area Manager and later as Division Chief. In 2008, he left Almirall to continue working in the family business, where he took charge of the real estate area as the Chairman of The Landon Group.

Other significant Boards to which he belongs

Caser Seguros, Acornseekers, Goodnews, Newwork co-working.

Member category

External proprietary director linked to Grupo Plafin, S.A. and Grupo Corporativo Landon, S.L.

Date of first appointment, and subsequent appointments

First appointment 25/07/14 by co-option; re-elected on 07/11/14, on 08/05/19 and on 07/05/21.

Company shares, and share options

Direct holder of 182 shares and indirect holder, together with other family members through the company Grupo Plafin, S.A., of 72,973,972 company shares, and indirect holder, together with other family members through Grupo Corporativo Landon, S.L., of 33,539,172 company shares.

Ms. Alexandra B. Kimball

Professional profile and biography

Dr. Alexandra B. Kimball holds an AB in Molecular Biology from Princeton University, an MD from Yale University School of Medicine, and an MPH from Johns Hopkins School of Public Health. Professor Kimball is the President and CEO of Harvard Medical Faculty Physicians (HMFPP) at Beth Israel Deaconess Medical Centre (BIDMC), member of the BIDMC Board of Directors and a dermatologist at the same centre. She is a Professor of Dermatology at the Harvard Medical School, as well as the Co-Chair of the Management Board at Beth Israel Lahey Health Performance Network (BILPN). She has led over 150 clinical trials in a wide range of diseases examining drug safety, efficacy, and dosing, published more than 350 papers, and served on several Data Safety Monitoring Boards, including for the NIH. In recognition of her research on physician workforce economics, quality of life, and outcomes, she was awarded the American Skin Association Research Award for Health Policy and Medical Education and the Mass General Hospital Bowditch Prize. Other awards include Mentor of the Year from the Women's Derm Society and the Outstanding Physician-Clinician and Lifetime Achievement Awards from the National Psoriasis Foundation. Dr Kimball has served on the non-profit Boards of the Society for Investigative Dermatology, the Massachusetts Foundation for the Humanities and Public Policy, and the Hidradenitis Suppurativa Foundation. She is past President of the International Psoriasis Council and serves on the Advisory Committee to the Director of the National Institutes of Health.

Other significant Boards to which she belongs

Beth Israel Lahey Health, Beth Israel Deaconess Medical Center, Physicians LLC.

Member category

Independent director.

Date of first appointment, and subsequent appointments

First appointment on 24/07/20; re-elected on 07/05/21.

Company shares, and share options

None.

Ms. Eva-Lotta Coulter (Known as Allan)

Professional profile and biography

Ms. Eva-Lotta Coulter holds a degree in Natural Sciences (Jakobsbergskolan, Stockholm) and Microbiology (Laboratory School University, Stockholm), and a Master Certificate in Marketing (Institute for Higher Marketing Business School, Stockholm). Ms. Coulter is also non-executive director of Aleta Biotherapeutics and Crescendo Biologics, Chairman and member of the Nomination Committee at C4X Discovery and non-executive director and member of the Corporate Governance Committee and the R&D Subcommittee at Targovax ASA. In the past Ms. Coulter held several relevant positions in other companies of the medical sector.

Boards of Directors of relevance to which Ms. Coulter belongs, whether in listed or non-listed companies

Aleta Biotherapeutics, Crescendo Biologics, C4X Discovery and Targovax ASA.

Director category

Independent.

Shares or options on shares in the Company

None.

Mr. Ruud Dobber

Professional profile and biography

Master of Science (University of Utrecht, The Netherlands) and PhD in Immunology (University of Leiden, The Netherlands). Mr. Dobber was appointed in January 2019 Executive Vice-President, BioPharmaceuticals Business in AstraZeneca and is responsible for product strategy and commercial delivery for Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology. Prior to this, Mr. Dobber held several executive roles at AstraZeneca, among others President at AstraZeneca US and Executive Vice-President North America, Executive Vice-President Europe, Regional Vice-President Europe, Middle East and Africa, Regional Vice-President Asia Pacific or Area Vice-President Europe 1. In addition, Mr. Dobber was a member of the Board and Executive Committee of EFPIA and Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America.

Other significant Boards to which he belongs, listed companies or otherwise

None.

Member category

Independent director.

Date of first appointment as company board member, and subsequent appointments

18/06/21, by the Shareholders Meeting.

Company shares, and share options, of which he is holder.

None.